Sheba Medical Center
Ramat Gan, Israel
Location status: Recruiting
Location contact
Alex Zvulunov, MD, MHA
PRINCIPAL_INVESTIGATOR
Naama Study coordinator
CONTACT
Silvina Friedlander-Barenboim, DMD
SUB_INVESTIGATOR
NCT Number: NCT07118280
The goal of this observational study is to explore whether oral health and saliva viscosity and composition in Oculopharyngeal Muscular Dystrophy (OPMD) is different from control subjects.
The main questions it aims to answer are:
Do swallowing disturbances in OPMD adversely affect oral health? Is saliva thickness (viscosity) is increased in OPMD? Does saliva in OPMD contains biochemical markers of the disease?
Interested in participating?
Request Info18 year and older
All sexes
Observational
Ramat Gan, Israel
Location status: Recruiting
Alex Zvulunov, MD, MHA
PRINCIPAL_INVESTIGATOR
Naama Study coordinator
CONTACT
Silvina Friedlander-Barenboim, DMD
SUB_INVESTIGATOR
The objectives of this observational study is to investigate oral health, saliva rheology and explore biochemical markers in OPMD. specifically to determine if anecdotal reports of "thick saliva" represent a previously unrecognized manifestation of the disease.
Oculo-pharyngeal muscular dystrophy (OPMD) is a rare, late-onset, hereditary (OMIM 164300) progressive degenerative muscle disease characterized by oro-pharyngeal dysphagia and eyelid ptosis and skeletal muscle weakness.
Oro-pharyngeal dysphagia is associated with impaired oral health in elderly patients in general, in patients with neurodegenerative diseases and in Parkinson's disease. Yet, oral health in OPMD has not been explored so far. Additionally, a notion in one report that more than half of patients with OPMD complained about "having thick saliva" has not triggered further research of saliva properties in OPMD.
OPMD patients enrolled in IsrOPMD registry at the multidisciplinary OPMD service at the Sheba Medical Center will be offered to participate in the study. Unaffected spouse or household member of each patient will be offered to serve as a control. Subjects younger than 18 years of age and those with any condition that may affect a composition of saliva were excluded from this study.
All study subjects will proceed a thorough stomatological examination documenting the number of decayed, missing and filled teeth (DMFT index), dryness of oral mucosa, presence of tongue coating, atrophic papillae, cleft or geographic tongue, gingival inflammation and gross saliva secretion, unstimulated whole saliva flow rate and saliva viscosity. Untargeted metabolomic analysis of the saliva will be performed.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Upon enrollment in the study
Viscosity of unstimulated whole saliva
Time frame: Upon enrollment in the study
DMFT, presence of tongue coating, clinical appearance of saliva and saliva-related complains
Time frame: Upon enrollment in the study
Differences in concentration of metabolites in unstimulated whole saliva of patients and control groups.
Contact information is provided by the study sponsor or research team.
Sheba Medical Center
Other Gov
Saliva Composition in Oculo-Pharyngeal Muscular Dystrophy (OPMD)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06185673
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn
New York, United States
View Trial DetailsNCT02877784
Articulation Disorders, Communication Disorders
Gainesville, Florida, United States
View Trial DetailsNCT02015481
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn
Los Angeles, California, United States
View Trial DetailsNCT07146256
Blepharoptosis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Ramat Gan, Israel
View Trial Details